Innovation

Incor Lifesciences will use State of the Art Technology and AI based Tools as applicable to achieve our mission.

Incor Laboratories

State-of-the-art labs

A pharma company with dedicated laboratories situated at the Indian Institute of Chemical Technology, Hyderabad, and also the corporate headquarters in the city. The integral unit employs advanced Artificial Intelligence for chemical process design and continuous flow manufacturing.

Incor Lifesciences India also has over 5 projects that are currently running along with the production of 9+ products. With a bunch of like-minded peers, they are driving steadily towards massive progression in the field.

Incor Lifesciences has a R&D Organization in India called “INCOR Laboratories Ltd.” and an R&D Setup in Howard University USA, that is responsible for selected emerging technology efforts.
Incor Lifesciences state-of-the-art labs will comprise of a dedicated team of researchers and will be headed by Stalwarts from pharma industry with a combined experience of 100 years.
Both R&D labs are situated in an academic environment, which enables Incor Lifescience to have access to highly trained researchers and intellectual input.
The presence of R&D lab in an academic environment, has the right eco-system for collaboration and partnership.

ILS has a R&D Organization in India called “INCOR Laboratories Ltd.” and an R&D Setup in Howard University USA, that is responsible for selected emerging technology efforts.

ILS’s state-of-the-art labs will comprise of a dedicated team of researchers and will be headed by Stalwarts from pharma industry with a combined experience of 100 years.

Both R&D labs are situated in an academic environment, which enables ILS to have access to highly trained researchers and intellectual input.

The presence of R&D lab in an academic environment, has the right eco-system for collaboration and partnership.

Artificial Intelligence – Building technology with cost efficiency

Incor Lifesciences will utilize AI tools to develop routes for small molecule APIs, peptides & co-crystals leading to the manufacturing of commercially viable drug substances which not only can lower costs by 20% to 40 % but also reduce time to market.

During the process we will strive to achieve global cost parity and environmental superiority with existing producers throughout the world establishing Incor Lifesciences as a leader in the API industry.

Enhancing Fermentation Process

Use of AI to re-introduce fermentation to recreate US capability to manufacture APIs including b-lactams, macrolides, and steroids.
Organocatalysis to replace fermentation with large reductions in scale and RM Inputs to produce staple APIs with high-price and/or high-volume opportunities.
In coordination with our peptides effort the Company has the potential to develop. produce and market human insulin through optimizing the manufacturing process and thereby offer a lower cost alternative to this product group that has become politically charged due to high pricing

Technologies we are going to focus on - Novel Technologies

Artificial Intelligence
Continuous manufacturing of APIs where this provides significant advantages and is consistent with regulatory expectations
Organocatalytic and New Routes of Synthesis to re-establish US capabilities for key classes of APIs
New approach to treating organic hazardous waste, enabling huge reductions in environmental burden and costs
Orphan Drugs and 505(b)(2)s

Green Manufacturing

Incor Lifesciences will also adopt Continuous Flow Chemistry as it offers the advantage of expediting the development time by eliminating the scaleup process which enables reduction in the development process by weeks/months.
Continuous Processing to realize up to 50% reduction in manufacturing costs from reduced capital/ labor & environmental costs
With continuous manufacture you engineer the process to reduce capital cost, labor cost, Solvent usage and with better control; Making it a GREEN ENV.

Perfecting our regulated process flow

We aspire to continue contributing towards enriching the quality of life on a global scale. At Incor, we are steadily steering towards the creation of innovative pharmaceuticals with diverse medical needs. We also want to do this by upholding the highest of ethical standards as we go about touching human lives.

Critical findings

Be it any complex dosages or formulations, we have the right experts who can take care of it all to arrive at the right findings.
Hardware

We have an establishment that houses a fully automated integral flow machine of continuous semi-autonomous nature.
Chemical R&D

Novel chemical routes to make Intermediates and APIs is what our entire R&D segment is progressing towards.

Target Audience

Pharma Cos

Currently dependent on China for KSM/Intermediates/APIs Pharma Cos looking for innovative products. Procure from Renovis

Agents

Currently procuring KSMs, intermediates from China. Procure from Renovis

Governments

Dependent on China for essential medicine stockpile. Renovis can consult and help setup on-shore production

Building an IP Bank

Intellectual Property

Chemical R&D

Novel chemical routes to make Intermediates and APIs. Currently multiple IPs under filing

Continuous Flow Process R&D

Process patents on the development of novel chemical processes on continuous flow.

Hardware

Design patents on fully integrated, automated and semi autonomous Continuous flow machines. Including Solvent recovery and effluent treatment units. Option to spin out as a separate company

Peptide - A New Age Pharma

Incor Lifesciences will emphasize exploiting emerging technical trends in the pharma industry so that within two years we can begin selling high value-added peptides & Co-Crystals which will have clinically enhanced results.

Incor Lifesciences will develop Co-Crystals for 505(b)2 for the US market, possibly providing the basis for entering the market with finished dosage form products.

We intend to offer the next-generation small molecule APIs, Peptide & Co-Crystal technologies providing access to customers and US patients a product and cost based competitive advantage.

Co-Crystals drugs in the market

Some Examples of Co-crystal drugs in market

Molecular structures of A. ipragliflozin (API) and B. l-proline (conformer).

Molecular complex of valsartan and sacubitril (multidrug cocrystal).

Chemical structures of A. Ertugliflozin and B. l-pyroglutamic acid.

Molecular structures of A. escitalopram and B. oxalic acid.

As a company, we are looked up to as frontiers in the pharmaceutical segment and we strive to set new standards for the medicine world to follow each day.